top stories

Pas­cal So­ri­ot and As­traZeneca com­mit to ze­ro-car­bon by 2025, car­bon-neu­tral by 2030. Where's the rest of Phar­ma?

3 hours ago
R&D

UP­DAT­ED: New play­ers are jump­ing in­to the scram­ble to de­vel­op a vac­cine as pan­dem­ic pan­ic spreads fast

3 hours ago
R&D

Fresh tri­al da­ta for­ti­fy po­si­tion of Roche's oral ther­a­py in spinal mus­cu­lar at­ro­phy bat­tle­ground

3 hours ago
R&D

Eli Lil­ly’s $1.6B can­cer drug failed to spark even the slight­est pos­i­tive gain for pa­tients in its 1st PhI­II

14 minutes ago
R&D

Latest

Most read

UP­DAT­ED: FDA’s golodirsen CRL: Sarep­ta’s Duchenne drugs are dan­ger­ous to pa­tients, of­fer­ing on­ly a small ben­e­fit. ...

Yesterday
Regulatory

Am­gen aug­ments Asia foothold by tak­ing over Astel­las joint ven­ture in Japan

28 minutes ago
China
Deals

PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

42 minutes ago
Deals

The FDA has de­val­ued the gold stan­dard on R&D. And that threat­ens every­one in drug de­vel­op­ment

1 hour ago
Bioregnum
Regulatory

Roche cracks Chi­na's ADC mar­ket open as Kad­cy­la scores its first breast can­cer OK in the coun­try

3 hours ago
China
Pharma

Wuhan virus out­break trig­gers in­evitable small-biotech ral­ly

23 hours ago
Pharma
see latest stream
People

'Y­ou be­trayed that du­ty': For­mer con­gress­man Chris Collins sen­tenced to 26 months in jail for in­sid­er trad­ing

2 days ago

Bernie Sanders goes af­ter Bio­Mar­in's shot at a record drug price, threat­en­ing to break the patent

2 days ago

Chi­na’s fourth rich­est man takes a back seat at the top drug­mak­er he built

6 days ago
Startups

French-Bel­gian biotech banks €20M to break ground in blood-splat­tered field of ther­a­peu­tic can­cer vac­cines

Yesterday

Boehringer, No­vo-backed Ger­man biotech banks €11M in liv­er re­gen­er­a­tion push

2 days ago

Take­da hops on­to $61M round for CRISPR play­er syn­the­siz­ing Cas9 al­ter­na­tives

Last week
Deals

Chica­go in­vestor de­vis­es £250M deal as re­al es­tate grows with UK's biotech sec­tor

Yesterday

In ac­tive shop­ping mode, Eli Lil­ly plots one deal per quar­ter as it scouts 'Der­mi­ra-like' as­sets up to $5B

6 days ago

Neon Ther­a­peu­tics makes one last re­treat, sell­ing it­self cheap in a bar­gain base­ment M&A deal

Last week
IPOs

Brex­it fears, Wood­ford woes over­shad­owed UK biotech and cut 2019 fi­nanc­ing by al­most half

Yesterday

First Chi­nese biotech on Nas­daq in two years draws $104M

6 days ago

Shoot­ing for $100M IPO, Schrödinger takes the wraps off its five in­ter­nal drugs and dis­clos­es deal de­tails

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of ...

Last week
People
R&D

Watch live: End­points at #JPM20

Last week

Just how big is the bio­phar­ma deal­mak­ing world? In 2019 we saw mega­bil­lions in cash change hands, and that's just the ...

2 weeks ago
Deals

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

3 weeks ago
Pharma
Special

Don't missSee all

UP­DAT­ED: FDA hands off its lat­est whirl­wind drug OK as Hori­zon hus­tles would-be block­buster to the mar­ket

Yesterday
Pharma
Regulatory

As­traZeneca plans to spend $535M-plus to ex­pand its R&D net­work and man­u­fac­tur­ing ops in France

Yesterday
Pharma

What do Mass Gen­er­al, the NCI and Mayo Clin­ic have in com­mon? They rou­tine­ly blow off an FDA rule on post­ing tri­al ...

2 days ago
R&D

GSK’s ‘break­through’ BC­MA can­cer drug gets a pri­or­i­ty re­view — and a big win for the on­col­o­gy R&D team

2 days ago
R&D

Endpoints Standouts

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

3 weeks ago
Pharma
Special

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

2 months ago
People
R&D

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

Last month
Publisher's note

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

3 months ago

Peer review See all

Jan
17

Pe­ter Ciriel­lo takes over the reins at Vy­gon USA; Mirum Phar­ma­ceu­ti­cals taps Ian Clements to the role of CFO

Jan
10

Eli Lil­ly vet jumps aboard Po­laris Part­ners; Mi­rati shakes up its lead­er­ship team with new hires and pro­mo­tions

Jan
3

IQVIA vet takes the helm at Chi­na's Foun­tain Med­ical; Michael Nazak pro­mot­ed to CFO post at Aridis

Dec
20

Bill Lund­berg takes over the reins at Merus; For­mer Akcea COO Jef­frey Gold­berg takes the helm of Im­mu­ni­tas

Dec
13

Shehnaaz Suli­man dives back in­to Alzheimer's at Alec­tor; Pyx­is re­cruits Spring­Works founder Lara Sul­li­van as CEO

R&D channel feed

2 days ago

BeiGene lines up its first shot at crack­ing the megablock­buster PD-1 mar­ket for lung can­cer. But can they over­come un­der­dog sta­tus?

BeiGene took an­oth­er big step to­wards chal­leng­ing Mer­ck, Bris­tol-My­ers Squibb, As­traZeneca and some oth­er Big Phar­ma heavy­weights for a share of the lu­cra­tive lung can­cer mar­ket for the ...

READ MORE

Rev­o­lu­tion Med shoots for $100M+ IPO — and di­vulges some se­crets about that Warp Dri­ve buy­out

4 days ago

Io­n­is, Akcea boost­ed by a pos­i­tive PhII for their No­var­tis castoff car­dio drug — and they plan to push ahead in­to ...

Yesterday
latest in R&D

Tran­si­tion­al lead­ers take charge as FDA be­gins PhI­II of OND re­or­ga­ni­za­tion

Yesterday

Sci­en­tists find un­ex­pect­ed an­ti-can­cer ac­tiv­i­ty in range of non-on­col­o­gy drugs — study

2 days ago
Discovery

As­traZeneca nabs pri­or­i­ty re­view for Lyn­parza in prostate as PARP in­hibitors ex­pand to more can­cers

2 days ago

At #JPM20, two CEOs, two rad­i­cal­ly dif­fer­ent ther­a­pies, and a fight to chase down sick­le cell

5 days ago
Cell/Gene Tx
Pharma

No­vo Nordisk's block­buster Ozem­pic wins FDA la­bel boost with CV in­di­ca­tion

6 days ago
see latest stories

Pharma channel feed

Yesterday

Eli Lil­ly re­serves $470M for new man­u­fac­tur­ing plant — and North Car­oli­na is more than pleased

Eli Lil­ly is adding an eighth site to its net­work of man­u­fac­tur­ing plants in the US, in­vest­ing $470 mil­lion to be­gin pro­duc­tion of in­jectable prod­ucts and de­liv­ery de­vices at Re­search ...

READ MORE

GSK, Pfiz­er con­tra­dict on the fu­ture of con­sumer health JV — re­port

Last week

War­ren and Klobuchar say they can low­er drug prices with­out Con­gress’ help

Last week
People
latest in Pharma

Ab­b­Vie's Skyrizi hangs No­var­tis' Cosen­tyx out to dry in head-to-head pso­ri­a­sis study

Last week

#JPM20: 'The NPV is al­ways wrong.' Take­da preps an­oth­er spin­out — this time on psych

Last week
R&D

Roche aims to 'un­der­whelm' with ris­diplam price as it en­ters SMA ri­val­ry with Bio­gen, No­var­tis — re­port

Last week

Amar­in's Vas­cepa reigns supreme in fish oil bat­tle, as As­traZeneca's ri­val fiz­zles

Last week
R&D

Alex­is Borisy has $200M to back a mar­ket-based plan aimed at cur­ing Amer­i­ca’s drug pric­ing ‘sick­ness’

Last week
Venture
see latest stories